𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma

✍ Scribed by Lizzia Raffaghello; Gabriella Pagnan; Fabio Pastorino; Emilio Cosimo; Chiara Brignole; Danilo Marimpietri; Paolo G. Montaldo; Claudia Gambini; Theresa M. Allen; Emil Bogenmann; Mirco Ponzoni

Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
313 KB
Volume
104
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. In advanced disease stages, prognosis is poor and treatments have limited efficacy, thus novel strategies are warranted. The synthetic retinoid Fenretinide (HPR) induces apoptosis in NB and melanoma cell lines. We reported an in vitro potentiation of HPR effects on melanoma cells when the drug is incorporated into GD2-targeted immunoliposomes (anti-GD2-SIL-HPR). We investigated the antitumor activity of anti-GD2-SIL-HPR against NB cells, both in vitro and in vivo. Anti-GD2-SIL showed specific, competitive binding to and uptake by, various NB cell lines. In in vitro cytotoxicity studies, NB cells, incubated with 30 microM HPR entrapped in anti-GD2-immunoliposomes, showed a significant reduction in cellular growth compared to free HPR, HPR entrapped in Ab-free liposomes or anti-GD2 empty liposomes. In an in vivo NB metastatic model, we demonstrated that anti-GD2-SIL-HPR completely inhibited the development of macroscopic and microscopic metastases in comparison to controls. Similar, but significantly less potent, antitumor effect was observed also in mice treated with anti-GD2 immunoliposomes without HPR (anti-GD2-SIL-blank) or anti-GD2 MAb alone (p = 0.0297 and p = 0.0294, respectively, vs. anti-GD2-SIL-HPR). Moreover, our results clearly demonstrated that although anti-GD2 MAb had a strong antitumor effect in this in vivo NB model, 100% curability was obtained only after treatment with anti-GD2-SIL-HPR (p < 0.0001). Anti-GD2 liposomal HPR should receive clinical evaluation as adjuvant therapy of neuroblastoma.

📜 SIMILAR VOLUMES

In vitro and in vivo antitumor effect of
In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma
✍ Judit Dobos; József Tímár; József Bocsi; Zsuzsanna Burián; Katalin Nagy; Gábor B 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB 👁 1 views

## Abstract 2‐methoxyestradiol (2ME~2~) is an endogenous metabolite of estradiol with estrogen‐receptor‐independent antitumor and antiangiogenic activity. We examined the effects of 2ME~2~ on the cellular proliferation of 8 human melanoma cell lines. We show that 2ME~2~ inhibited cell proliferation

Selective antibody-mediated targeting of
Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo
✍ Hila Novak; Roy Noy; Kfir Oved; Dina Segal; Winfried S. Wels; Yoram Reiter 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 276 KB 👁 1 views

## Abstract Epidermal growth factor receptor (EGFR) is highly overexpressed in many tumor types. We present a new fusion molecule that can target solid tumors that express EGFR. The fusion molecule combines the advantage(s) of the well‐established tumor targeting capabilities of high affinity recom